MICHAEL BEST STRATEGIES LLC

Lobbying for SAREPTA THERAPEUTICS · Medical research and drug development company

Filing 2nd Quarter - Termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

Massachusetts

Representation ended

May 12, 2026

The registrant reported terminating its work for this client.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Medical/Disease Research/Clinical Labs

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.